Outlook Therapeutics Inc (OTLK)

[VMLG17]

pfelg, you were close, but a little more time is needed until the pps reaches $2. As OTLK management has stated, the BLA should be completed by end of 1Q 2022, or any day now, and the corresponding PR should also boost the share price with FDA approval being very possible before the end of the year. Hopefully, that momentum will be maintained headed into 2023.